New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs

- Vaccine Discovery Partnership (VxDP) announcement at the Foundation’s Grand Challenges Meeting in Rio de Janeiro signals commitment to find solutions to the challenges facing the developing world

Issued: Tuesday 29 October 2013, London UK; Rio, Brazil; Seattle, US

GSK and the Bill & Melinda Gates Foundation (BMGF) today announced the launch of a new joint initiative that will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration. GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability.

Most vaccines must be kept cold and transported under constant refrigeration via a so-called ‘cold chain’ which is a significant challenge in hot, remote and resource-limited regions.

Details of the Vaccine Discovery Partnership (VxDP) under which this initiative falls were unveiled this morning at the Foundation’s Grand Challenges Meeting in Rio de Janeiro, Brazil. In one of the first projects to start under this initiative, GSK researchers will explore how to make adjuvants – a critical component of some vaccines – more heat stable.

“Developing a thermostable adjuvant is an important and ambitious goal. This partnership is the starting point for research into an exciting area of biomedical technology that has the potential to overcome a significant and long-standing barrier to vaccine access in developing countries,” commented Emmanuel Hanon, Senior Vice President, Vaccine Discovery and Development, GSK. “At GSK, we believe that by working together we will find innovative solutions to the world’s biggest health problems.”

This project will focus initially on the adjuvant AS01 which is used in GSK’s RTS,S malaria vaccine candidate, currently in late-stage development in partnership with the PATH Malaria Vaccine Initiative. RTS,S has been designed for use in infants and children from sub-Saharan Africa, where maintaining vaccines at an optimum temperature can be challenging. Developing a method of making AS01 more heat stable could bring a significant public health benefit. The results could also have broader applications for all other AS01-containing vaccines, including vaccines in development by GSK against HIV and tuberculosis.

“Vaccines are one of the most powerful tools to save and improve lives, and this partnership with GSK will help drive research and development efforts to overcome persistent global health challenges,” said Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation. “Reducing the dependence on the cold chain is critical to the affordable delivery of life-saving vaccines to the children who need them most.”

Despite significant progress over the last decade, over 22 million children in developing nations remain without access to life-saving vaccines. Reducing dependence on the cold chain is a key approach to support the effective and affordable delivery of vaccines for global health.

The VxDP, instigated by the BMGF, aims to integrate key players in vaccine development – biotechnology institutions, pharmaceutical companies, non-government organisations (NGOs) and academia – to drive advances in vaccine research and development (R&D) that have the potential to transform global health. Projects funded through the VxDP will look to solve some of the world’s most intractable health problems, including barriers to vaccine access.

GSK is in on-going discussions with the Foundation to shape and plan additional projects with relevance to global health that can be initiated through this new collaboration.

Notes to Editors:

 

About AS01 and RTS,S

AS01 is the adjuvant used in GSK’s RTS,S malaria vaccine candidate. GSK is also developing other AS01-containing vaccines against HIV and tuberculosis.

RTS,S, the world’s most advanced malaria vaccine candidate, is being developed in partnership by GSK and the PATH Malaria Vaccine Initiative (MVI), together with prominent African research centres and their Northern academic research partners. RTS,S aims to help protect infants and young children living in malaria-endemic areas of Africa against infection and clinical disease caused by plasmodium falciparum, the most deadly type of malaria parasite.

About the Vaccine Discovery Partnership (VxDP)

The Vaccine Discovery Partnership (VxDP) is a novel funding programme initiated by the Bill & Melinda Gates Foundation to enhance innovation in the development of vaccines for global health. Under a Memorandum of Understanding (MoU) framework, the VxDP will oversee a range of projects with multiple industry partners. Projects funded through the VxDP will span preclinical to experimental Phase IIa trials. These projects may be of relatively high risk, such that they would be difficult for any one organisation to fund without the partnership. The Foundation will set aside funds to support pilot projects and partnering companies will contribute matching resources and expertise while also committing that advances will support those who need them most through global access provisions.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.


GSK enquiries:

 

 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Simon Steel

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

 

Sarah Alspach

+1 202 715 1048

(Washington, DC)

 

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

 

 

 

 

Analyst/Investor enquiries:

Sally Jackson

+44 20 8047 5543

(London)

 

Kirsty Collins (SRI & CG)

+44 20 8047 5534

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

 

Lucy Singah

+44 (0) 20 8047 2248

(London)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.